Chinese Billionaire Zhang Lei is Selling These 5 Stocks

01. argenx SE (NASDAQ:ARGX)

Number of Hedge Fund Holders as of Q2 2022: 35

The Dutch biotechnology firm argenx SE (NASDAQ:ARGX) specializes in creating cures for autoimmune conditions. Its treatments focus on conditions like neuropathy, myopathy, cancer, and airway inflammation. The company is based in Breda, the Netherlands.

Zhang Lei’s first quarter of 2022 stake in argenx SE (NASDAQ:ARGX) was worth $37.8 million and it came in the form of 120,000 shares. During the second quarter, this entire stake was sold by Zhang Lei’s fund. argenx SE (NASDAQ:ARGX)’s largest investor is Kurt Von Emster’s VenBio Select Advisor, which owns 1.2 million shares that are worth $479 million.

Artisan Partners discussed argenx SE (NASDAQ:ARGX) in the second quarter investor letter. Here is what the fund said:

“argenx SE (NASDAQ:ARGX) is a commercial stage biotechnology company with an approved, first-, and potentially best-in-class therapy (FcRn) for autoimmune diseases. In its first full quarter of sales, Vyvgart meaningfully exceeded consensus sales expectations, indicating strong early market traction. In addition, it released positive phase 3 results for Vyvgart’s use in treating immune thrombocytopenia purpura, a blood disorder characterized by low platelet levels. We believe this second indication could receive FDA approval in early 2023, and the news confirms our thesis that Vyvgart is a “pipeline in a product”—a compelling new molecule which is likely to be safe and effective in numerous rare autoimmune disorders.”

You can also take a peek at 10 Russell 2000 Basic Materials Dividend Stocks to Buy and 10 Utilities Stocks with Over 3% Dividend Yield.

Follow Insider Monkey on Twitter